EvolutionaryScale is backed by AWS and Nvidia | Credit: Getty Images / metamorworks

US AI startup EvolutionaryScale has raised $142m in seed funding to develop AI that can generate novel proteins for use in scientific research, drug discovery and medical therapies.

The funding, announced on Tuesday (25 June), will allow the AI startup to develop a stronger partnership with the biotech industry, the company’s co-founder and chief scientist Alexander Rives said.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Founded in 2023, EvolutionaryScale is backed by leading companies such as Amazon and Nvidia.

The AI startup is also collaborating with Amazon Web Services (AWS) and NVIDIA to accelerate applications from drug discovery to synthetic biology with AI.

EvolutionaryScale recently unveiled its newest product, ESM3, a GenAI model that allows for the creation of novel proteins.

ESM3 will be able to create novel proteins that would have otherwise taken 500 million years to evolve naturally.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

EvolutionaryScale has taken “a step toward a future” where AI is woven into the world of biology, Rives said.

The new AI model can be used by businesses for a wide range of purposes, varying from the development of cancer treatments to carbon capture.

GlobalData forecasts that the global market for AI in the medical devices industry is set to grow at a compound annual growth rate (CAGR) of 29.1% from $336m in 2023 to $1.2bn in 2027.